THT Biomaterials GmbH aims to overcome major methodological issues at the bottom of today’s drug development, tissue engineering and regenerative medicine research practices leading to false positive or negative results. A new visionary platform technology is under development that will speed up research as it makes its results more realistic by replacing animal components with human components (https://tht-biomaterials.com).
R&D:In vitro toxicoty, in vitro diagnostics (cancer)/drug development. Bioaktive tissue-ink. 2D coating/3D gel. Organoids. Filler and wound healing.
Production:HUMAN PLACENTA Collagen-I, liquid or freece-dried. HUMAN PLACENTA Laminin-111. HUMAN PLACENTA Substrate (hpS).
Dr.-Bohr-Gasse 7
Wien
Wien
Contact: Johannes Hackethal (CTO)
Email: office@tht-biomaterials.com
Website